SKINHEALTH SYSTEMS INC (SKIN)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.69-1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · SKIN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on improving operating income and reducing net losses as a key financial priority over multiple quarters.
Stated as a priority in 5 of last 5 quarters. Operating income improved from a loss of $6.24M in 2025-Q3 to a positive $3.57M in 2026-Q2, with net losses narrowing but still negative. The trajectory shows delivering progress on improving operating income and reducing net losses.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Operating income improved to $3.57 million in 2026-Q2.”
“Operating loss narrowed to $1.8 million in 2026-Q1.”
“Operating income was $0.16 million in 2025-Q4.”
“Operating loss was $6.24 million in 2025-Q3.”
“Operating loss was $2.7 million in 2025-Q2.”
Management aims to grow and stabilize revenue, with quarterly fluctuations but a general focus on increasing sales.
Stated as a priority in 5 of last 5 quarters. Revenue showed fluctuations, rising from $64.9M in 2026-Q1 to $72.1M in 2026-Q2, but was lower than $82.4M in 2025-Q4. The trajectory shows some progress but remains volatile, indicating limited progress toward stable growth.
“Revenue grew to $72.1 million in 2026-Q2.”
“Revenue was $64.9 million in 2026-Q1.”
“Revenue was $82.4 million in 2025-Q4.”
“Revenue was $70.7 million in 2025-Q3.”
“Revenue was $78.2 million in 2025-Q2.”
Address recent senior executive departures and maintain leadership stability as a priority.
Stated as a priority in 3 of last 5 quarters. Management disclosed key executive departures including COO and Chief Revenue Officer in 2026. These leadership changes represent a challenge to stability, with limited evidence of replacement or stabilization so far.
“COO Sheri Lewis is resigning to pursue other opportunities.”
“Chief Revenue Officer Ronald Menezes was terminated without cause.”
“Chief Revenue Officer Ronald Menezes terminated without cause.”
Over the trailing year it converted 0.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates, the US dollar (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.